SG11201605126YA - Ex vivo antibody production - Google Patents

Ex vivo antibody production

Info

Publication number
SG11201605126YA
SG11201605126YA SG11201605126YA SG11201605126YA SG11201605126YA SG 11201605126Y A SG11201605126Y A SG 11201605126YA SG 11201605126Y A SG11201605126Y A SG 11201605126YA SG 11201605126Y A SG11201605126Y A SG 11201605126YA SG 11201605126Y A SG11201605126Y A SG 11201605126YA
Authority
SG
Singapore
Prior art keywords
antibody production
vivo antibody
vivo
production
antibody
Prior art date
Application number
SG11201605126YA
Other languages
English (en)
Inventor
Helden Pauline Maria Wilhelmina Van
Mark Jeroen Kwakkenbos
Hergen Spits
Tim Beaumont
Original Assignee
Aimm Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimm Therapeutics Bv filed Critical Aimm Therapeutics Bv
Publication of SG11201605126YA publication Critical patent/SG11201605126YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SG11201605126YA 2013-12-24 2014-12-24 Ex vivo antibody production SG11201605126YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13199584 2013-12-24
PCT/NL2014/050908 WO2015099534A1 (en) 2013-12-24 2014-12-24 Ex vivo antibody production

Publications (1)

Publication Number Publication Date
SG11201605126YA true SG11201605126YA (en) 2016-07-28

Family

ID=49885067

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201605126YA SG11201605126YA (en) 2013-12-24 2014-12-24 Ex vivo antibody production

Country Status (15)

Country Link
US (2) US20170009205A1 (ja)
EP (2) EP3087177B1 (ja)
JP (1) JP6832705B2 (ja)
CN (1) CN106029873A (ja)
AU (1) AU2014370516B9 (ja)
BR (1) BR112016014881B1 (ja)
CA (1) CA2934660C (ja)
DK (1) DK3087177T3 (ja)
EA (1) EA201691112A1 (ja)
ES (1) ES2927905T3 (ja)
HU (1) HUE060145T2 (ja)
IL (1) IL246409B (ja)
MX (1) MX2016008345A (ja)
SG (1) SG11201605126YA (ja)
WO (1) WO2015099534A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2646466T3 (en) * 2010-12-02 2017-06-06 Aimm Therapeutics Bv METHODS AND METHODS FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
CN116554353B (zh) * 2023-04-28 2024-05-03 北京奇迈永华生物科技有限公司 一种假病毒高效感染人nk细胞及其他免疫细胞的方法
CN118459577A (zh) * 2024-07-09 2024-08-09 浙江康佰裕生物科技有限公司 逆转录包膜蛋白GALV env蛋白及其抗体的制备

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4343708B2 (ja) * 2002-04-26 2009-10-14 アンスティテュ ナシナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル−イ．エヌ．エス．ウ．エール．エム． 改良型キメラ糖タンパク質と、類型化されたレンチウイルス
ATE474853T1 (de) * 2005-08-03 2010-08-15 Therapeutic Human Polyclonals Unterdrückung der b-zell apoptose in transgenen tieren die humanisierte immunglobulingene exprimieren
AU2006323315B2 (en) * 2005-12-09 2014-02-20 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of antibody producing cells
CA2768207C (en) 2009-07-15 2019-12-03 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
ES2434256T3 (es) * 2010-05-28 2013-12-16 F. Hoffmann-La Roche Ag Método de cultivo de células B individuales y producción de anticuerpos específicos
DK2646466T3 (en) * 2010-12-02 2017-06-06 Aimm Therapeutics Bv METHODS AND METHODS FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
WO2013076139A1 (en) * 2011-11-23 2013-05-30 F. Hoffmann-La Roche Ag Cd40l expressing mammalian cells and their use
WO2014109696A1 (en) * 2013-01-10 2014-07-17 Alf Grandien Method for immortalization of b cells and uses thereof
AU2015211480B2 (en) * 2014-01-31 2020-05-14 Kling Biotherapeutics B.V. Means and methods for producing stable antibodies

Also Published As

Publication number Publication date
US12084681B2 (en) 2024-09-10
US20170009205A1 (en) 2017-01-12
IL246409A0 (en) 2016-08-31
US20200149007A1 (en) 2020-05-14
WO2015099534A1 (en) 2015-07-02
MX2016008345A (es) 2017-02-08
CN106029873A (zh) 2016-10-12
DK3087177T3 (da) 2022-10-03
JP6832705B2 (ja) 2021-02-24
BR112016014881B1 (pt) 2023-03-28
CA2934660A1 (en) 2015-07-02
JP2017500052A (ja) 2017-01-05
EP3087177A1 (en) 2016-11-02
AU2014370516A1 (en) 2016-07-07
EP4141108A1 (en) 2023-03-01
BR112016014881A8 (pt) 2020-06-09
ES2927905T3 (es) 2022-11-11
IL246409B (en) 2022-01-01
EP3087177B1 (en) 2022-09-14
EA201691112A1 (ru) 2017-01-30
AU2014370516B2 (en) 2021-03-11
AU2014370516B9 (en) 2021-07-29
HUE060145T2 (hu) 2023-02-28
NZ722156A (en) 2021-08-27
CA2934660C (en) 2023-03-14
BR112016014881A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
IL269528A (en) Anti- FCRH5 antibodies
HK1217023A1 (zh) 新型抗體
GB201322583D0 (en) Antibodies
HK1220142A1 (zh) 抗體
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
GB201300706D0 (en) Antibody
IL245488A0 (en) Anti- ccl17 antibodies
GB201312226D0 (en) Improved antibodies
IL246409A0 (en) Production of antibodies outside the body of the animal
GB201318283D0 (en) Antibodies